MOLN logo

Molecular Partners AGNasdaqGS:MOLN Stock Report

Market Cap US$149.0m
Share Price
US$3.92
US$11.2
65.0% undervalued intrinsic discount
1Y4.3%
7D1.0%
1D
Portfolio Value
​
View

Molecular Partners AG

NasdaqGS:MOLN Stock Report

Market Cap: US$149.0m

Molecular Partners (MOLN) Stock Overview

A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. More details

MOLN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 48.96% per year

Risk Analysis

Makes less than USD$1m in revenue (CHF0)

Currently unprofitable and not forecast to become profitable over the next 3 years


MOLN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Molecular Partners AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Molecular Partners
Historical stock prices
Current Share PriceCHF 3.92
52 Week HighCHF 5.36
52 Week LowCHF 3.41
Beta0.71
1 Month Change2.08%
3 Month Change-13.75%
1 Year Change4.26%
3 Year Change-39.75%
5 Year Change-79.79%
Change since IPO-80.05%

Recent News & Updates

Recent updates

Seeking Alpha • Jan 15

Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs

Summary Molecular Partners AG leverages a novel DARPin platform for targeted cancer therapies, with promising early-stage candidates like MP0533 and MP0317 in clinical trials. Financially, MOLN has a cash runway of 2-2.5 years, but future funding remains uncertain, posing a risk for long-term sustainability. Strengths include innovative approaches and a diverse pipeline, but the lack of a clear frontrunner and early-stage focus are significant risks. Despite uncertainties, MOLN's valuation at $200 million presents a ground-floor investment opportunity, warranting a tentative “Buy” with awareness of inherent risks. Read the full article on Seeking Alpha
Seeking Alpha • Aug 07

Molecular Partners: A Speculative Bet On Innovative DARPin Technology

Summary Molecular Partners develops DARPin proteins for oncology and virology, offering advantages over traditional antibodies. The company's Switch-DARPin platform offers conditional and reversible immune activation, which benefits vulnerable populations needing targeted, customizable therapies. MOLN's pipeline includes MP0533, MP0621, and MP0317, with collaborations on MP0712 and other preclinical programs. MOLN trades at a $203.7 million market cap with significant cash reserves but faces high cash burn and potential future capital raises. Despite biotech risks, MOLN's highly differentiated IP and sufficient resources make it a speculative "buy" for investors interested in unique oncology and virology biotechs. Read the full article on Seeking Alpha
Seeking Alpha • Aug 25

Molecular Partners GAAP EPS of CHF4.59, revenue of CHF184.5M

Molecular Partners press release (NASDAQ:MOLN): 1H GAAP EPS of CHF4.59. Revenue of CHF184.5M (+4093.2% Y/Y). Strong financial position with CHF 285.1 million in cash (including short term deposits) as of June 30, 202. Company expected to be funded into 2026, excluding any potential payments from R&D partnerships.

Shareholder Returns

MOLNUS BiotechsUS Market
7D1.0%2.5%2.2%
1Y4.3%28.7%24.8%

Return vs Industry: MOLN underperformed the US Biotechs industry which returned 28.7% over the past year.

Return vs Market: MOLN underperformed the US Market which returned 24.8% over the past year.

Price Volatility

Is MOLN's price volatile compared to industry and market?
MOLN volatility
MOLN Average Weekly Movement8.2%
Biotechs Industry Average Movement10.4%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: MOLN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MOLN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004134Patrick Amstutzwww.molecularpartners.com

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers.

Molecular Partners AG Fundamentals Summary

How do Molecular Partners's earnings and revenue compare to its market cap?
MOLN fundamental statistics
Market capUS$149.04m
Earnings (TTM)-US$73.19m
Revenue (TTM)n/a
0.0x
P/S Ratio
-2.0x
P/E Ratio

Is MOLN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MOLN income statement (TTM)
RevenueCHF 0
Cost of RevenueCHF 36.66m
Gross Profit-CHF 36.66m
Other ExpensesCHF 21.36m
Earnings-CHF 58.02m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 25, 2026

Earnings per share (EPS)-1.55
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did MOLN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/16 22:37
End of Day Share Price 2026/06/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecular Partners AG is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert BurnsH.C. Wainwright & Co.
Richard VosserJ.P. Morgan
Wei ChangLeerink Partners LLC